Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Decreases By 51.3%

P3 Health Partners Inc. (NASDAQ:PIII) was the recipient of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 138,133 shares, a decline of 51.3% from the May 14th total of 283,541 shares. Based on an average daily trading volume, of 1,072,122 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.3% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in P3 Health Partners stock. Diversified Trust Co acquired a new position in P3 Health Partners Inc. (NASDAQ:PIII) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,316 shares of the company’s stock, valued at approximately $63,000. Diversified Trust Co owned about 0.28% of P3 Health Partners as of its most recent filing with the Securities and Exchange Commission. 7.75% of the stock is owned by hedge funds and other institutional investors.

P3 Health Partners Stock Performance

PIII stock opened at $12.23 on Friday. The company has a market cap of $88.55 million, a P/E ratio of -0.32 and a beta of 1.60. The stock’s 50 day simple moving average is $6.88 and its 200 day simple moving average is $4.53. P3 Health Partners has a fifty-two week low of $1.52 and a fifty-two week high of $16.89.

P3 Health Partners (NASDAQ:PIII) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.85) by $5.17. P3 Health Partners had a negative net margin of 8.57% and a negative return on equity of 302.33%. The business had revenue of $386.39 million during the quarter, compared to analyst estimates of $391.45 million.

Analyst Upgrades and Downgrades

PIII has been the subject of several recent analyst reports. TD Cowen reaffirmed a “hold” rating and set a $14.00 price objective (up from $3.00) on shares of P3 Health Partners in a research report on Friday, May 22nd. Lake Street Capital reiterated a “buy” rating and set a $14.00 target price (up from $4.00) on shares of P3 Health Partners in a research report on Friday, May 15th. UBS Group set a $14.00 target price on shares of P3 Health Partners in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded shares of P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.00.

P3 Health Partners Company Profile

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.